Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure by Smart, Neil A. et al.
Clinical Medicine Insights: Cardiology 2011:5 55–66
doi: 10.4137/CMC.S4309
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Cardiology
revIew
Clinical Medicine Insights: Cardiology 2011:5  55
Bucindolol: A pharmacogenomic perspective  
on Its Use in chronic Heart Failure
Neil A. Smart1, Nigel Kwok1, David J. Holland2, rohan Jayasighe3 and Francesco Giallauria4
1School of Science and Technology, University of New england, Armidale, NSw 2351, Australia. 2The School of 
Science and Technology, University of New england, Armidale, NSw 2351, Australia. 3Director of Cardiology / Director 
of Comprehensive Heart Failure Service, Gold Coast Hospital / Professor of Cardiology, Griffith University, Australia. 
4Department of Clinical Medicine, Cardiovascular and Immunological Sciences, Cardiac rehabilitation Unit, University of 
Naples “Federico II”. Corresponding author email: nsmart2@une.edu.au
Abstract: Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic   sympatholytic   activity. 
The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was 
terminated prematurely and failed to show an overall mortality benefit. However, benefits on cardiac mortality and   re-  hospitalization 
rates were observed in the BEST trial. Bucindolol has not shown benefits in African Americans, those with   significantly low ejection 
fraction and those in NYHA class IV heart failure. These observations could be due to the exaggerated sympatholytic response to 
  bucindolol in these sub-groups that may be mediated by genetic polymorphisms or changes in gene regulation due to advanced heart 
failure. This paper provides a timely clinical update on the use of bucindolol in chronic heart failure.
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Introduction
Despite initial misgivings, the beneficial role of beta 
(β)-blocker  therapy in  chronic  heart  failure (CHF) 
has been well proven in clinical trials.1 However there 
remains debate regarding the use of specific β-blockers 
for individual New York Heart Association (NYHA) 
heart failure categories.2 Adrenergic drive is enhanced 
as a compensatory mechanism in heart failure and this 
has prognostic implications.   Counteracting the adren-
ergic  drive  with  β-blocker  therapy  seems  to  offer 
long-term  symptomatic  and    prognostic  benefits  in 
heart failure patients.3,4   Bucindolol is a non-  selective 
β-antagonist that may offer benefit to certain groups 
of patients with heart failure in NYHA class I-III,5 but 
not other patient groups, such as African Americans.6 
This review will describe the mechanism of action of 
bucindolol,  review  evidence  from  relevant  clinical 
trials, and evaluate efficacy and safety in the use of 
bucindolol in the different sub groups of heart failure 
patients.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Compensatory neurohormonal activation is a   primary 
adaptive  response  in  CHF,  employed  to  maintain 
  cardiac  output  and  preserve  the  perfusion  of  vital 
organs. However, short-term cardiovascular support 
afforded by sympathetic hyperactivation is clinically 
negated by the poor long-term prognosis associated 
with altered β-adrenergic receptor sensitivity, which 
may lead to decompensation and increased suscepti-
bility to ventricular tachy-arrhythmias.7 β-adrenergic 
receptor blockade has been effectively employed in 
patients with CHF to counter the enhanced sympathetic 
  activity and improve mortality, cardiovascular function 
and clinical status.8 Bucindolol is a third-  generation, 
non-selective β-adrenergic   receptor blocker, that acts 
on  both  β-1  and  β-2  receptors.    Bucindolol’s  addi-
tional α-1 antagonistic activity contributes to its mild 
  vasodilator effect.7 Bucindolol’s neurohormonal activ-
ity profile is similar to that of carvedilol but different 
in some respect to older agents.9
An  important  attribute  in  the  classification  of 
β-adrenergic  agents  is  the  presence  or  absence  of 
intrinsic  sympathomimetic  activity  (ISA).  Early 
  studies trialing bucindolol reported no ISA in human 
myocardium,10,11  however,  a  later  study  measuring 
intracellular cyclic AMP observed bucindolol to have 
partial agonist activity at the β-adrenergic receptor.12 At 
present, the effect of bucindolol on ISA appears to be 
unresolved. Bucindolol is a lipophilic compound with a 
high hepatic first-pass metabolism through the hepatic 
cytochrome P450 pathway.7 Increased plasma concen-
trations may occur in patients with hepatic impairment 
necessitating caution and possible dose decrement.
early Mechanistic studies  
of Bucindolol
Due to the conflicting results and inconclusive data 
from research carried out thus far, the precise role 
of bucindolol in the management of CHF remains 
  debatable. Several trials have examined the effect of 
bucindolol on hemodynamic responses and/or ven-
tricular function10,13–15 with the drug consistently dem-
onstrating  improvement  in  left  ventricular  ejection 
fraction and cardiac index while reducing left ventric-
ular filling pressures, pulmonary artery pressures, and 
heart rate in CHF. In addition, bucindolol has been 
shown to increase stroke volume and minute work 
without  increasing  myocardial  oxygen  demand.13 
The latter fact suggests some increase in   myocardial 
efficiency,  although  comparisons  did  not  reach 
  statistical significance in the trial by Eichhorn and 
colleagues.13 The improved ventricular performance 
may be   predominantly due to the enhanced cardiac 
  contractility and not due to the modest   vasodilator 
effect.13 This improvement in contractility has been 
confirmed  by  relatively  load-independent  methods 
(end-systolic elastance and the maximum dP/dt and 
end-diastolic volume relations).13 Bucindolol reduces 
isovolumic relaxation times despite having little effect 
on chamber stiffness (over a 3-month trial period).13
The  improvement  in  cardiac  performance 
with bucindolol appears to be greatest in patients with 
  idiopathic  dilated  cardiomyopathy  compared  with 
patients with ischemic heart disease, although there 
does appear to be benefits in these patients also.15 
Underlying mechanisms of this variation in treatment 
  benefits is unclear, and some proposed reasons include: 
(1) increased adrenergic down-regulation that exists 
in  idiopathic  dilated  cardiomyopathy    compared  to 
  ischemic cardiomyopathy; (2) β-adrenergic   receptors 
in left and right ventricles of patients with   ischemic 
heart  failure  demonstrate  a  moderate  degree  of Bucindolol in chronic heart failure
Clinical Medicine Insights: Cardiology 2011:5  57
uncoupling from pharmacologic response compared 
with idiopathic dilated cardiomyopathy;15,16 (3) The 
patterns of connective tissue scar formation may be 
different in idiopathic versus ischemic groups;17 and 
(4) ongoing ischemia may exist in the ischemic group 
preventing efficient substrate utilization.10,18 Several 
studies examining the effect upon NYHA class have 
demonstrated  improvement  with  bucindolol,10,13–15 
however  this  improvement  has  not  translated  to 
increases  in  exercise  tolerance  or  increased  maxi-
mal oxygen consumption. However, all β-blockers 
(including  bucindolol),  have  been  shown  to  blunt 
exercise tolerance even in patients without objective 
evidence of heart failure,19 probably by limitation of 
cardiac output (heart rate).
Bucindolol clinical Trials
Early bucindolol trials were small and of short dura-
tion and focused on softer end points rather than hard 
endpoints such as mortality and hospitalization. These 
trials  showed  conclusive  improvements  in  cardiac 
function, control of hypertension and quality of life 
(QOL), but equivocal data for peak oxygen consump-
tion (peak VO2). Table 1 summarizes the published 
trials of bucindolol to date.
The first clinical trial to test bucindolol was car-
ried out amongst asthmatics (without heart failure) 
to  assess  its  bronchoconstrictor  effect.  This  study 
showed a 25% incidence of bronchoconstriction with 
bucindolol use.20 In addition, the remainder of patients 
demonstrated an impaired bronchodilator response to 
salbutamol, independent of baseline pulmonary func-
tion and consistent with a traditional dose-response 
relationship.20  The  early  bucindolol  heart  failure 
trials were carried out in small and   heterogeneous 
  populations. Eichorn et al conducted a cohort analy-
sis in 15 patients with heart failure. In this trial, car-
diac contractility was improved, despite unchanged 
chamber  stiffness  or  efficiency,  without  reducing 
myocardial oxygen consumption in post-myocardial 
infarction patients with left ventricular dysfunction.13 
Bristow also found exercise tolerance to be preserved 
or  increased  with  three  different  doses  of  bucin-
dolol  in  patients  with  left  ventricular  dysfunction, 
but left ventricular ejection fraction only improved 
at  the  highest  (200  mg)  dose.21  Small  studies  by 
Gilbert10 (idiopathic etiology) and Pollock14 (mixed 
etiology), also showed improved left ventricular ejec-
tion fraction and symptoms at a dose of 200 mg in 
patients with cardiomyopathies of various etiology. 
  Anderson16 reported 23 month follow up data from the 
same patient group as Gilbert10 and showed improved 
left ventricular ejection fraction, NYHA functional 
class  and  stable  maximal  oxygen  uptake.  Perhaps 
the most important finding of   Anderson’s work was 
that all 20 patients survived the full duration of fol-
low up leading to the recommendation of a larger 
trial.   Contemporaneously, this same group reported 
isolated  improvements  in  left  ventricular  ejection 
fraction, left ventricular chamber   dimensions, filling 
Table 1. Clinical trials of bucindolol to date.
study patients subjects Dose(s) mg ⋅ d−1 Duration
Ruffin20 COPD/asthma 16 50, 100, 200 Acute
eichorn13,# NYHA I (7%), II (47%), III (33%), Iv (13%) 15 150–200 12 weeks
Bristow21 NYHA class II (43%) and III (57%) 141 12.5, 50, 200 12 weeks
Gilbert10,‡ NYHA II (43%), III (57%) 23 200 12 weeks
Pollock14 NYHA II (5%), III (74%), Iv (21%) 19 200 12 weeks
Anderson16,‡ NYHA II (50%), III (50%) 20 25–200 2 years
woodley15,‡ NYHA II (37%), III (67%) 49 170–200 12 weeks
Bristow22 NYHA I (1%), II (43%), (55%), Iv (1%) 139 12.5, 50, 200 12 weeks
Heesch23,∞ 27/30 non-ischemic NYHA I–Iv (% n/a) 30 200 12 weeks
BeST25,* NYHA III (92%) Iv (8%) 2708 100 (,75 kg), 200 (.75 kg) 2 years*
Torp-Pederson26  
BeAT*
NYHA I (45%), II (43%), III (10%), Iv (2%) 343 100 (,75 kg), 200 (.75 kg) Ongoing*
notes: #Study not a randomized, controlled trial; ‡Some duplication of subjects between these studies; ∞Comparator was Metoprolol; *Study stopped 
prematurely.
Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; NYHA, New York Heart Association Functional Class; BeST, Beta Blocker evaluation 
of Survival Trial.Smart et al
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pressures and circulating norepinephrine levels, after 
bucindolol therapy in heart failure due to idiopathic 
dilated  cardiomyopathy,  although  this  observation 
was not seen in, patients with ischemic heart failure.15 
A dose-  response analysis reported a larger improve-
ment  in  left  ventricular  ejection  fraction  at  higher 
doses.22 A  head  to  head  comparison  of  bucindolol 
and the β-1 selective controlled-release metoprolol 
in  heart  failure  patients  concluded  that  the  former 
produced  more  favorable  improvements  in  resting 
cardiac index and end-diastolic pressure. The latter 
agent was observed to reduce coronary blood flow 
and myocardial   oxygen consumption.23
The positive observations in smaller trials proved 
the need for a well structured large randomized, con-
trolled trial to gather more conclusive outcomes data 
on bucindolol therapy in heart failure. As a result, in 
1995 the Beta-Blocker Evaluation of Survival Trial 
(BEST) study protocol was published.24 BEST was 
designed to study whether bucindolol, would reduce 
all cause mortality in patients with advanced heart 
failure  as  the  primary  end  point  and  to  assess  its 
effect in various subgroups of heart failure patients 
as defined by ethnic background and demographic 
criteria. Secondary end points were total cardiovas-
cular  mortality,  mortality  due  to  worsening  heart 
failure, sudden death, quality of life, hospitalization 
and its cost, left ventricular ejection fraction after 3 
and 12 months of therapy, and myocardial infarction. 
Further analysis was carried out to study the effect of 
heart failure etiology, ethnicity and gender on the out-
come measures.24,25 The BEST study failed to show 
significant  reductions  in  mortality  at  the    seventh 
interim  analysis  in  mid-1999,  after  a  mean  (final) 
  follow  up  period  of  2  years.25  Subject  withdrawal 
was very low and compliance to therapy was 81% in 
both arms of the study. However, the secondary end-
points  of  cardiovascular  death  and  hospitalization 
were significantly lower in the bucindolol group. The 
bucindolol group also showed greater improvement 
in left ventricular ejection fraction, which was also 
significant (bucindolol 5.5% ± 7.8% versus placebo 
2.1 ± 13.4, P , 0.001).
The  BEST  study  group  and  the  control  group 
were well matched for NYHA class, left ventricular 
ejection  fraction  and  optimal  background  therapy, 
nevertheless,  the  protocol  administration  may  have 
varied between the 90 administering sites. A total of 
449 patients in the placebo group (33%), and 411 in 
the bucindolol group died during the study and fol-
low up period (30%); (hazard ratio [HR] = 0.90; 95% 
confidence interval (CI) = 0.78 to 1.02; unadjusted 
P = 0.10; adjusted P = 0.13), a non significant trend. 
The annual mortality in the placebo group was 17% 
and 15% in the bucindolol group. The rate of death 
from cardiovascular causes was significantly lower in 
the bucindolol group (HR = 0.86; 95% CI = 0.74–0.99; 
P = 0.04). The rates of death due to pump failure and 
sudden death showed trend to the lower; these results 
are comparable to the overall effect on the rate of 
death from cardiovascular causes.25 Table 2 compares 
BEST mortality data with those of the other placebo 
controlled trials of β-blocker therapy in heart failure.
Bucindolol  significantly  reduced  the  heart  fail-
ure related hospital readmission rates (HR = 0.78; 
95% CI = 0.69 to 0.88; P , 0.001) but there was a 
Table 2. Placebo-controlled heart-failure trials involving β-blockers—all cause mortality.
  study B-blocker IsA nYHA  
class
number  
of patients
All-cause  
mortality
P value
Positive  
trials
CIBIS II3 Bisoprolol  
(high β-1 selective)
No III–Iv 2649 ↓34% ,0.0001
MerIT65 Metoprolol succinate  
(mod β-1 selective)
No II–Iv 3991 ↓34% ,0.0001
COPerNICUS78 Carvedilol  
(non-selective + α-blocker)
No Iv 2289 ↓35% ,0.0014
Negative  
trials
BeST25 Bucindolol  
(weak α-blocker + non 
selective)
25% ISA III–Iv 2708 ↓10% ,0.10
SeNIOrS79 Nebivolol  
(β-1 selective)
Both β-2  
and β-3 ISA
II–Iv 2128 ↓12% ,0.21
Abbreviations: NYHA, New York Heart Association; ISA, Intrinsic Sympathomimetic Activity.Bucindolol in chronic heart failure
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  non-significant reduction in all-cause hospitalization 
rates (HR = 0.92; 95% CI = 0.84 to 1.01; P = 0.08). 
Bucindolol reduced the average number of hospital-
izations and the average number of inpatient days 
per patient. The combined end point of death or heart 
transplantation during the trial occurred in 32% of the 
patients in the bucindolol group and 35% in the placebo 
group (HR = 0.87; 95% CI = 0.77–0.99; P = 0.04).25 
Left  ventricular  ejection  fraction  was  improved 
with bucindolol therapy at 3 months compared with 
  placebo (5.5% ± 7.8% vs. 2.1% ± 6.9% in the placebo 
group; P , 0.001) and at 12 months (7.3% ± 10.0% 
vs. 3.3% ± 8.7% for placebo; P , 0.001). Authors 
also  found  a  trend  toward  improved  survival  with 
bucindolol among patients in NYHA class III, but 
not in class IV, with a HR of 0.87 (95% CI = 0.75 to 
1.01; P = 0.06); for those with a left ventricular ejec-
tion fraction greater than 20 percent, the HR was 0.83 
(95% CI = 0.69 to 1.00; P = 0.05).
The BEST study is the largest trial of bucindolol in 
heart failure patients to date and the decision to pre-
maturely terminate BEST had an effect on the imple-
mentation of the 2000-patient Bucindolol Evaluation 
in  Acute  myocardial  infarction  Trials  (BEAT).26 
BEAT studied bucindolol’s effects on the mortality in 
post-myocardial infarction (MI) heart failure patients, 
but only 343 patients were recruited before BEAT 
was  also  terminated  prematurely.  The    analysis  of 
the   outcomes data in the recruited subjects in BEAT 
showed a non-significant trend towards a mortality 
benefit in the bucindolol group.26
Several other subsequent sub-analyses of BEST 
data suggest certain heart failure patients groups are 
less likely to benefit from bucindolol therapy, these 
studies are summarized in Table 3. O’Connor et al27 
reported a 52% (P = 0.001) reduction in non-fatal MI 
in those receiving bucindolol, but in those that were 
suspected of having MI, the 2 year mortality rate was 
higher (56% versus 30%; P = 0.01). The benefit of 
bucindolol therapy was not proven in heart failure 
patients  with  NYHA  class  IV  symptoms,  African 
Americans or those with a left ventricular ejection 
fraction ,20%, although these observations are not 
without dispute.2 Various reasons have been exam-
ined to explain the reduced effects of bucindolol in 
certain heart failure sub-groups. One such explana-
tion involves the existence of several different poly-
morphisms  of  the  β-1  adrenergenic  receptor  gene 
(ADRB1) and variants of the pre-junctional adrener-
genic receptor that may affect the clinical response 
to bucindolol therapy. Others have attributed bucin-
dolol’s failure to produce significant reductions in all-
cause mortality to its ISA.28
Table 4 summarizes the gene polymorphisms rel-
evant  to  the  individual’s  response  to  therapy  with 
β-blockers. Both the variant 389Gly and 49Gly alleles 
Table 3. BeST sub-analyses.
study n Finding(s)
Anderson5 226 Class Iv patients were high risk for early risk of death or heart failure  
hospitalization were not reduced.
Domanski37 1668 Different heart failure sub-groups respond differently to β-blocker therapy.
Ghali53 2708 Prognostic predictive values of some variables vary between women and men.  
Survival advantage of women is confined to patients with non-ischemic etiology.
eichorn64 79 Patients without contractile reserve have higher resting adrenergic drive, (higher)   
plasma norepinephrine, and may experience greater ISA effects from bucindolol.
Bristow80 2126 Likelihood ratios indicated 18% of bucindolol group but only 1% of placebo  
group had an increased risk of death related to reduction in norepinephrine  
at 3 months due to sympatholysis, which compromised bucindolol efficacy.
O’Connor27 2708 Bucindolol appears to attenuate the risk of non-fatal MI.
Liggett36 1040 Beta-1 Arg-389 polymorphism affects (amplifies) therapeutic response 
to bucindolol in heart failure.
Tate77 2708 Bucindolol improves quality of life.
Frantz73 206 Lack of effect of bucindolol on natriuretic peptides appears consistent  
with lack of overall efficacy.
Bristow42 1040 Patients who were α2c Del carriers (heterozygous or homozygous) were  
more likely to exhibit an ISA response to bucindolol which did not translate  
into a survival benefit as it did (by 30%) in α2c wild type carriers.Smart et al
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of the ADRB1 gene occur more frequently in African 
Americans than Caucasians.29 The distribution of the 
Arg389 allele of the β-1 adrenergenic receptor also 
appears to vary based on ethnicity;   Chinese (74%), 
Caucasians  (72%),  Hispanics  (67%)  and  African-
Americans  (58%).30  In  vitro,  these  polymorphisms 
have been shown to affect the function of the receptor 
as well as its cell signaling.31,32 Specifically, data dem-
onstrated that the wild type 389Arg and 49Ser alleles 
to be associated with increased in-vitro   activity. These 
observations suggest that patients with certain allelic 
variants  of  the  β-1  adrenergic  receptor  (ADRB1) 
would have a superior help prevent adverse cardiac 
remodeling,  but  possibly  harmful  to  patients  with 
extremely severe cardiac dysfunction that are likely 
to be dependent on adrenergic support.2
ADrB1 polymorphisms
In both animal models33 and healthy African   American 
subjects34 with the 389Arg phenotype showed a greater 
reduction in left ventricular diameter and improve-
ment in left ventricular ejection fraction. Heart failure 
subjects with the 49Ser genotype have a higher mortal-
ity rate as compared to the 49Gly genotype; however, 
the use of β-blocker therapy has shown to mitigate 
this difference.35 Retrospective analysis of BEST data 
identified that patients with the arginine, rather than 
glycine, phenotype of β-1-  Arg-389 exhibit a supe-
rior norepinephrine   lowering response to   bucindolol 
  therapy.36  Large  reductions  in  norepinephrine  have 
been associated with increased mortality rates prob-
ably due to those with worst cardiac function being 
most  reliant  on  adrenergic  drive  for  the  mainte-
nance of cardiac pump function and   hemodynamics.2 
 Moreover the arginine   phenotype has been reported to 
be less prevalent in non-  Caucasian patients and may 
therefore explain why a sub-analysis of BEST data, 
with 100%   Caucasian patients, produced a   significant 
all-cause mortality benefit with a HR of 0.77 (95% 
CI = 0.65 to 0.92; P = 0.004).37 Cruikshank2 argues 
racial   differences in polymorphisms do not explain 
the non-significant mortality data from BEST as a 
sub-study of the MERIT-HF trial found no associa-
tion  between  heart  failure  outcome  or  response  to 
β-blocker therapy (metoprolol) and the Arg389 geno-
type.38 However, Domanski’s (2003) comparison of a 
sub-analysis of 1668 BEST patients, together with the 
results from three other β-blocker trials, showed an all-
cause mortality benefit with bucindolol therapy when 
African Americans were removed from the analysis.37 
This latter study is difficult to interpret because statis-
tical analysis of interaction between ADRB1 genotype 
and treatment and their association with the outcome 
was not included in the publication. Another study of 
637 patients with heart failure enrolled in registries 
found no association between β-receptor genotypes 
and survival in heart failure with sustained-release 
metoprolol and carvedilol therapy.39
Pre-junctional adrenergenic  
receptor variants
The  regulation  of  cardiac  adrenergic  activity  is 
  complex  and  involves  mechanisms    modulating 
  central   sympathetic outflow, norepinephrine   neuronal 
synthesis, pre-junctional norepinephrine release, and 
neuronal  reuptake  of  norepinephrine.40    Adrenergic 
activity  is  also  likely  to  be  influenced  by  genetic 
  variation, particularly in adrenergic receptors (ARs) 
that  regulate  norepinephrine  release,  such  as  the 
α2C-AR,  which  is  present  in  the  pre-junctional 
adrenergic nerve   terminals where it provides tonic 
inhibition of norepinephrine release.41 Recent work 
on pre-junctional adrenergenic receptors reported that 
patients who were 2C Del322-325 carriers (heterozy-
gotes  or  homozygotes)  exhibited  a  much  greater 
ISA response to bucindolol.42 The same authors also 
showed decreased norepinephrine activity at 3 months 
compared with placebo patients of 2C wild type (stan-
dard or common type).42 A genetic sub-study of BEST 
(n  =  1040)  evaluated  the    association  between  the 
Table 4. relevant gene polymorphsims to β-blockers.
Gene polymorphisms studied Type of alteration*
ADrB1 Arg389Gly; Ser49Gly Pharmacodynamic
ADrB2 Arg16Gly; Glu27Gln Pharmacodynamic
CYP2D6 (eg, metoprolol, carvedilol) Pharmacokinetic
notes: *Pharmaco-kinetics is defined as what the body does to the drug; pharmaco-dynamics is defined as what the drug does to the body.Bucindolol in chronic heart failure
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ADRB1   Arg-389Gly and α2c Del322-325 polymor-
phisms and the effect on mortality with bucindolol 
therapy.43  Subjects  who  were  389Arg  homozygous 
had  a  statistically  higher  rate  of  overall  survival, 
with  bucindolol.  They  also  showed,  reduced  heart 
failure severity and cardiovascular re-  hospitalization 
with  bucindolol  therapy.  Conversely,  subjects  pos-
sessing the 389Gly allele had no response to bucin-
dolol therapy, but nothing remarkable was attributed 
to the α2c Del322-325 polymorphism.43 Prevalence 
of the α2c Del322-325 genetic variant is enriched in 
African-American populations, where it has an allele 
frequency of ∼0.40 compared with ∼0.04 in whites.44 
Based  on  animal  observations  that  norepinephrine 
release by isolated atria is increased41,45 it has been pre-
dicted that α2C Del322-325 variant in humans would 
be associated with increased systemic norepinephrine 
levels, particularly in situations such as heart failure 
where  central  sympathetic  outflow  is  increased.46 
Indeed, there is evidence that the α2C Del322-325 
polymorphism leads to an increased adrenergic activ-
ity in normal subjects,34 however, there is conflicting 
experimental  evidence  that  β-2-adrenoceptor  poly-
morphisms  significantly  influence  the  relationship 
between heart rate and cardiac adrenergic drive in 
heart failure39,47 and also whether this affects the rate 
of  norepinephrine  release  from  sympathetic  nerve 
  terminals.48 As a result, norepinephrine levels may fall 
to levels below that which can support cardiac func-
tion, predisposing the patient to adverse events that 
neutralize the beneficial effects of β-blockade. On the 
other hand, when the major “wild type” allele is pres-
ent in the homozygous state, bucindolol is likely to 
produce only mild and clinically beneficial degrees of 
norepinephrine lowering.
Safety
COPD patients
The use of β-blocker therapy in patients with chronic 
obstructive  pulmonary  disease  (COPD)  remains 
contentious. In a Cochrane systematic review, Sal-
peter et al found no evidence to suggest cardioselec-
tive β-blockers, given as a single dose or for longer 
duration, produced any change in forced expiratory 
volume over one second (FEV1) or change in respira-
tory symptoms compared to placebo.49 Furthermore 
the FEV1 treatment response to β-2 agonist was not 
affected.49 Moreover subgroup analysis revealed no 
change in results for those participants with severe 
COPD  or  for  those  with  a  reversible  obstructive 
  component. However the same author later suggested 
that the demonstrated benefit in heart failure, coronary 
artery disease and hypertension dictates that cardiose-
lective β-blockers should not be routinely withheld 
from patients with COPD.50 However β-2 agonist use 
in patients with COPD increases the risk for adverse 
cardiovascular events.50 It is well known that β-2 ago-
nists can induce tachycardia and hypokalemia. The 
benefits of β-blockade in COPD patients appear to 
outweigh any potential risk of side effects according 
to the available evidence.51 It is reasonable to avoid 
bucindolol in elderly COPD patients due to the higher 
prevalence of CHF in these older patients.52
Gender
Data from BEST reports that prognostic predictive 
values of some variables differ in magnitude between 
women  and  men.  The  survival  benefit  in  women 
is limited to those with heart failure due to a non-
ischemic etiology.53 However hormone replacement 
therapy is associated with a marked improvement in 
survival  in  postmenopausal  women  with  advanced 
heart failure.54
Diabetes
There appears little direct evidence to suggest bucin-
dolol  blocks  β-3  adrenergic  receptors.  It  has  been 
suggested that non-selective β-blockers may have a 
role in weight gain and metabolic changes that may 
adversely  impact  on  heart  failure  in  patients  with 
diabetes.2,55 A  sub-analysis  of  BEST  data  reported 
that diabetes worsens the prognosis in advanced heart 
failure, an observation limited to those with ischemic 
cardiomyopathy.56 Bucindolol may mask tachycardia 
and thus mask the symptoms of therapy induced hypo-
glycemia.57 Evidence exists that carvedilol, may pro-
mote a better metabolic profile in those with diabetes 
compared to metoprolol.58 Meta-analysis has shown 
that renin-angiotensin axis inhibitor agents may be 
preferable  to  β-Blockade  in  diabetics.59  Although 
those with diabetes mellitus and heart failure appear 
to derive prognostic benefit from β-blocker therapy, 
the magnitude of that benefit is blunted compared to 
the non-diabetics.60 Available evidence indicates that 
bucindolol is best avoided in the diabetics with heart 
failure due to ischemic etiology.Smart et al
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African Americans
Carvedilol should be preferred over bucindolol for 
the treatment of heart failure in African Americans 
based on the data from CAPRICORN61 and BEST,25 
where the former showed benefit with the latter show-
ing none.
NYHA class Iv and elderly patients
Previous work has shown that only a small propor-
tion of patients with decompensated heart failure are 
able to tolerate β-blocker therapy,62 especially NYHA 
class  IV.63  Heart  failure  patients  with  contractile 
reserve tend to demonstrate lower baseline norepi-
nephrine levels.64 Those patients without a reasonable 
contractile  reserve  may  not  tolerate  the  significant 
fall  in  norepinephrine  brought  on  by  bucindolol. 
This fact may contribute to the higher mortality rates 
observed in the patient sub-set with extremely low 
ejection fraction and decompensation.62,64 Combined 
data on NYHA class IV patients from MERIT-HF,65 
CIBIS-II3 and CIBIS66 show overall mortality benefits 
with β-blocker therapy.67 These analyses also suggest 
the findings for bucindolol in class IV patients should 
not be generalized to all β-blockers and that an alter-
native β-blocker, should probably chosen for elderly 
heart failure patients.68
Heart failure with preserved ejection fraction
Up to half of all heart failure presentations have normal 
left ventricular ejection fraction (HFpEF).69 Whilst 
β-blockade has been trialed in this patient subgroup, 
no  randomized,  controlled  trial  has    demonstrated 
treatment benefits on mortality.70 However, as patients 
with  HFpEF  are  often  older,  improving  symp-
toms (such as exercise tolerance) may present more 
appropriate and realistic outcomes. In a recent meta-
analysis of therapy in HFpEF, β-blockade increased 
exercise capacity despite no improvement in diastolic 
function.70 However, there have been no trials to date 
investigating the effects of bucindolol in HFpEF.
Drug metabolism and interactions
Bucindolol  metabolism  predominantly  involves 
hepatic cytochrome P450 pathways.7 Hence plasma 
levels of this drug may be affected by the   concomitant 
use of other drugs that are metabolised by the same 
pathways. Bucindolol may blunt the response to other 
β-  or  α-adrenergic  agonists.71  Patients  with  severe 
renal impairment or hepatic dysfunction may need 
dose alteration.71
Dosing
In lieu of the risk of acute decompensation upon initi-
ation of β-blocker therapy, bucindolol was titrated in 
the BEST study from an initial dose of 3 mg b.d.; up 
to a mean dose of about 75 mg b.d.25 These doses were 
well tolerated in BEST and doses as high as 200 mg 
have been trialed with no adverse effects and low 
(circa 9%) dropout rates.22 It has been suggested that 
if bucindolol were approved for use in heart failure a 
target dose of approximately 75 mg b.d. (the average 
value achieved in BEST) would be recommended.57
Adverse reactions
Significant adverse effects observed with bucindolol 
therapy include dizziness, diarrhea, hyperglycemia, 
bradycardia and intermittent claudication (P , 0.05). 
It is reasonable to assume that adverse effect profile of 
bucindolol to be similar to that of other β-blockers.
Efficacy
Bucindolol’s suggested effects on ISA may present a 
likely explanation for the observed negative outcome 
in BEST.28,72 A recent review suggested that the larger 
falls in norepinephrine were associated with higher 
mortality risk that is explained by the sympatholytic 
effect.2  A  neurohormonal  sub-study  of  206  BEST 
patients reported no change in serum brain natriuretic 
peptide levels following bucindolol therapy and this 
observation  is  consistent  with  the  overall  negative 
results in BEST.73
It should be noted that, in the BEST trial, a nomi-
nally  significant  interaction  effect  of    therapy  was 
found only for race (African American vs.   Caucasian) 
(χ2 = 5.06; P = 0.02). The apparent effect of race and 
treatment is the lack of benefit observed in African 
Americans (HR for death with bucindolol versus pla-
cebo = 1.17; 95% CI = 0.89 to 1.53; P = 0.27), compared 
to the significant survival benefit seen in non-Afri-
can Americans (HR = 0.82; 95% CI = 0.70 to 0.96; 
P = 0.01). The BEST trial   demonstrated that bucin-
dolol may not be beneficial to heart failure patients 
who are African Americans, with severe impairment 
of systolic function and who are decompensated.2Bucindolol in chronic heart failure
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Place in therapy
The retrospective analyses of BEST data looked into the 
genetic factors that determined the response to bucin-
dolol therapy. Currently genetic testing is being exam-
ined as a useful means whereby theraputic decisions 
could be made in relation to bucindolol. Bucindolol 
was reviewed by the Federal Drug Administration for 
the treatment of heart failure in 2009 and subsequently 
rejected.74 Nevertheless a European regulatory autho-
risation was issued in October 2010 to ARCA biop-
harma, Inc., that allowed bucindolol therapy in heart 
failure, but only following genetic testing.75 It is inter-
esting to note that ADRB1 genotype is associated with 
varying response to bucindolol therapy in CHF, but 
not in metoprolol or carvedilol therapy. More work is 
required to further explore the genetic associations of 
the response to bucindolol therapy in heart failure. It 
is also important to examine the healthcare economic 
implications related to genetic testing prior to therapy 
if relevant.
Patient tolerence
Studies showed that bucindolol therapy was associ-
ated with an improvement in NYHA class with no 
corresponding  improvement  in  exercise  tolerance 
or oxygen utilization.71 While peak VO2 is consid-
ered  a  strong  predictor  of  mortality  in  those  with 
cardiomyopathy,76 self-reported quality of life (QOL) 
measures have also been shown to predict mortality 
in BEST patients.77 Two of the four QOL question-
naires used in the BEST analysis reported bucindolol 
treated patients had improved QOL at 12 months.77 
Patients treated with bucindolol experienced signifi-
cantly less angina, tachycardia, insomnia, depression, 
palpitations and atrial fibrillation compared to those 
receiving placebo.25 However, side-effects were more 
common, with significantly more dizziness, diarrhea, 
hyperglycemia, bradycardia, and intermittent claudi-
cation in the bucindolol arm.57
conclusions
Bucindolol is a non-selective β-adrenergic receptor 
blocker, with α-1 blocker properties and mild ISA. 
The BEST study, which is the largest clinical trial 
of bucindolol in patients with CHF, was terminated 
  prematurely and failed to show an overall mortality 
benefit.  There  were,  however,  observed  benefits  in 
cardiac mortality and re-hospitalization rates in the 
BEST trial. Bucindolol has not shown benefits in Afri-
can Americans, those with significantly low ejection 
fraction and those in NYHA class IV heart failure. 
These observations could be due to the exaggerated 
sympatholytic  response  to  bucindolol  in  these  sub-
groups that may be mediated by genetic polymorphisms. 
In Europe bucindolol therapy is approved for heart 
failure therapy but only upon genetic testing. In light 
of this the healthcare economics implications of ther-
apy with bucindolol remains yet to be studied. Given 
the mixed results from the various studies published 
hitherto, the precise role and the use of bucindolol in 
the management of heart failure remains ill defined, 
especially  considering  the  effectiveness  of  current 
β-blockade and other therapies. Further studies and 
clinical trials based upon genetic testing are needed 
before we can clearly define the safety and efficacy of 
bucindolol in the management heart failure.
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